Parkinson's Disease and Related Disorders Part II

Home

Order to parcel locker
easy pay
PZWL

Reduced price

See next edition:

Parkinson's Disease and Related Disorders Part II

Handbook of Clinical Neurology Series

Authors:

Brand: Churchill Livingstone

ISBN: 9781416048190

1,105.00 zł

995.00 zł Save 110.00 zł Tax included

Lowest price within 30 days before promotion: 995.00 zł

Quantity

Product unavailable

Out of print

Notify me about new stock Enter your email address to get notifications about new stock of this product

Delivery policy

Choose Paczkomat Inpost, Orlen Paczka, DPD or Poczta Polska. Click for more details

Security policy

Pay with a quick bank transfer, payment card or cash on delivery. Click for more details

Return policy

If you are a consumer, you can return the goods within 14 days. Click for more details

Description

A volume in the Handbook of Clinical Neurology series on Parkinsons Disease and related disorders. Note that this is Part II of a two volume set on Parkinsons Disease by Koller and Melamed.

Product Details

Brand Churchill Livingstone

Reference 35012

EAN13 9781416048190

ISBN 9781416048190

Data sheet

Publication date: 2007
Issue number: 1
Cover: hard cover
Pages count: 530

Section 5 Medical Treatment of Parkinsons Disease

30. Physical therapy in Parkinsons disease
Jean-Michel Gracies, Winona Tse, Mara Lugassy and Judith Frank (New York, NY, USA)
31. Neuroprotection in Parkinsons disease:: clinical trials
Fabrizio Stocchi (Rome, Italy)
32. Levodopa
Thomas D. Hälbig and William C. Koller (New York, NY and Chapel Hill, NC, USA)
33. Dopamine agonists
Olivier Rascol, Tarik Slaoui, Wafa Regragui, Fabiene Ory-magne, Christine Brefel-Courbon and Jean-Louis Montastruc (Toulouse, France)
34. Monoamine oxidase A and B inhibitors in Parkinsons disease
Moussa B. H. Youdim and Peter F. Riederer (Haifa, Israel and Würzburg, Germany)
35. Anticholinergic medications
Yaroslau Compta and Eduardo Tolosa (Barcelona, Spain)
36. Antiglutamatergic drugs in the treatment of Parkinsons disease
Maria Graciela Cersósimo and Federico Eduardo Micheli (Buenos Aires, Argentina)
37. Investigational drugs
Carlo Colosimo and Giovanni Fabbrini (Rome, Italy)
38. The importance of patients groups and collaboration
Mary Baker and Jill Rasmussen (Sevenoaks and Redhill, UK)

Section 6 Complications of therapy

39. Motor and non-motor fluctuations
Susan H. Fox and Anthony E. Lang (Toronto, Canada)
40. Levodopa-induced dyskinesias in Parkinsons disease
Jose A. Obeso, Marcelo Merello, Maria C. Rodríguez-Oroz, Concepció Marin, Jorge Guridi, Lazaro Alvarez (Buenos Aires, Argentina, Pamplona and Barcelona, Spain and La Habana, Cuba)
41. Treatment induced mental changes in Parkinsons disease
Kelvin L. Chou and Joseph H. Friedman (Warwick, RI, USA)

Section 7 Surgical treatment

42. Ablative surgery for the treatment of Parkinsons disease
Frederick A. Lenz (Baltimore, MD, USA)
43. Deep brain stimulation
J. Volkmann and G. Deuschl (Kiel, Germany)
44. Transplantation
Curt R. Freed (TBC) (Denver, CO, USA)
45. Gene therapy approaches for the treatment of Parkinsons disease
Biplob Dass and Jeffrey H. Kordower (Chicago, IL, USA)

Section 7 Other parkinsonian disease syndromes

46. Multiple system atrophy
Ronald F. Pfeiffer (Memphis, TN, USA)
47. Progressive supranuclear palsy
David J. Burn and Andrew J. Lees (Newcastle upon Tyne and London, UK)
48. Corticobasal degeneration
Natividad P. Stover, Harrison C. Walker and Ray L. Watts (Birmingham, AL, USA)
49. Infectious basis to the pathogenesis of Parkinsons disease
V. Dhawan and K. Ray Chaudhuri (London, UK)
50. Toxic causes of Parkinsons disease
Nirit Lev, Eldad Melamed and Daniel Offen (Petah-Tikva and Tel-Aviv, Israel)
51. Drug induced parkinsonism
Federico Micheli and María Graciela Cersosimo (Buenos Aires, Argentina)
52. Vascular parkinsonism
Yacov Balash and Amos D. Korczyn (Tel-Aviv and Ramat-Aviv, Israel)
53. Old age and Parkinsons disease
Alex Rajput and Ali H. Rajput (Saskatoon, Canada)
54. Other degenerative processes
J. Carsten Möller and Wolfgang H. Oertel (Marburg, Germany)
55. Hydrocephalus and structural lesions
John G.L. Morris, Brian Owler, Mariese A. Hely and Victor S.C. Fung (Sydney, Australia)
56. Calcification of the basal ganglia
Jennifer S. Hui and Mark F. Lew (Los Angeles, CA, USA)
57. Trauma and Parkinsons disease
Oscar S. Gershanik (Buenos Aires, Argentina)
58. Psychogenic parkinsonism
Vasiliki Koukouni and Kailash P. Bhatia (London, USA)
59. Parkinsonism and dystonia
Ruth H. Walker (new York, NY, USA)
60. Dementia with Lewy bodies
Ian McKeith (Newcastle upon Tyne, UK)
61. Myoclonus and parkinsonism
Daniel D. Truong and Roongroj Bhidayasiri (Los Angeles, CA, USA and Bangkok, Thailand)